Trial · NCT02196324
Outcomes17
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Average Visual Analog Scale at Baseline | At Baseline | The Intent-to-treat (ITT) population - all randomized participants who were treated. This population was analyzed based upon the treatment to which participants were randomized. | Units on a scale | MEAN |
| PRIMARY | Average Visual Analog Scale at Week 2 | At Week 2 | The ITT population - all randomized participants who were treated. This population was analyzed based upon the treatment to which participants were randomized.~Here, overall number of participants analyzed signifies only the participants with available data that were analyzed for the outcome measure. | Units on a scale | MEAN |
| PRIMARY | Average Visual Analog Scale at Week 4 | At Week 4 | The ITT population - all randomized participants who were treated. This population was analyzed based upon the treatment to which participants were randomized.~Here, overall number of participants analyzed signifies only the participants with available data that were analyzed for the outcome measure. | Units on a scale | MEAN |
| PRIMARY | Average Visual Analog Scale at Week 8 | At Week 8 | Intent-to-treat (ITT) population - all randomized participants who were treated. This population was analyzed based upon the treatment to which participants were randomized.~Here, overall number of participants analyzed signifies only the participants with available data that were analyzed for the outcome measure. | Units on a scale | MEAN |
| SECONDARY | Number of Participants With Improvement in Pruritus as Reported on Verbal Rating Scale (VRS) - Pruritus | At Baseline and Week 8 | The ITT population - all randomized participants who were treated. This population was analyzed based upon the treatment to which participants were randomized.~Here, number analyzed in each row signifies only the participants with available data that were analyzed for each parameter. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Improvement in Burning as Reported on Verbal Rating Scale (VRS) - Burning | At Baseline and Week 8 | The ITT population - all randomized participants who were treated. This population was analyzed based upon the treatment to which participants were randomized.~Here, number analyzed in each row signifies only the participants with available data that were analyzed for each parameter. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Improvement in Stinging as Reported on Verbal Rating Scale (VRS) - Stinging | At Baseline and Week 8 | The ITT population - all randomized participants who were treated. This population was analyzed based upon the treatment to which participants were randomized.~Here, number analyzed in each row signifies only the participants with available data that were analyzed for each parameter. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Worst Visual Analog Scale (VAS) | At Baseline, Weeks 2, 4, and 8 | The ITT population - all randomized participants who were treated. This population was analyzed based upon the treatment to which participants were randomized.~Here, number analyzed in each row signifies only the participants with available data that were analyzed for each parameter. | Units on a scale | MEAN |
| SECONDARY | Number of Participants With Improvement in Pruritus as Reported on Patient Global Assessment (PGA) | At Weeks 2, 4, and 8 | The ITT population - all randomized participants who were treated. This population was analyzed based upon the treatment to which participants were randomized.~Here, number analyzed in each row signifies only the participants with available data that were analyzed for each parameter. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Numeric Rating Scale (NRS) | At Baseline, Weeks 2, 4, and 8 | The ITT population - all randomized participants who were treated. This population was analyzed based upon the treatment to which participants were randomized. | Units on a scale | MEAN |
| SECONDARY | Dermatology Life Quality Index (DLQI) | At Baseline, Weeks 2, 4, and 8 | The ITT population - all randomized participants who were treated. This population was analyzed based upon the treatment to which participants were randomized.~Here, number analyzed in each row signifies only the participants with available data that were analyzed for each parameter. | Units on a scale | MEAN |
| SECONDARY | Pruritus-specific Quality of Life (ItchyQoL) | At Baseline, Weeks 2, 4, and 8 | The ITT population - all randomized participants who were treated. This population was analyzed based upon the treatment to which participants were randomized.~Here, number analyzed in each row signifies only the participants with available data that were analyzed for each parameter. | Units on a scale | MEAN |
| SECONDARY | Patient Benefit Index, Version for Patients With Pruritus (PBI-P) | At Week 8 / End of Treatment | The ITT population - all randomized participants who were treated. This population was analyzed based upon the treatment to which participants were randomized.~Here, overall number of participants analyzed signifies only the participants with available data that were analyzed for the outcome measure. | Units on a scale | MEAN |
| SECONDARY | Number of Participants With Improvement in PN Lesions as Reported on Investigator Global Assessment (IGA) | At Week 8 | The ITT population - all randomized participants who were treated. This population was analyzed based upon the treatment to which participants were randomized.~Here, overall number of participants analyzed signifies only the participants with available data that were analyzed for the outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Improvement on Prurigo Activity Score (PAS) | At Day 1 and Week 8 | The ITT population - all randomized participants who were treated. This population was analyzed based upon the treatment to which participants were randomized.~Here, number analyzed in each row signifies only the participants with available data that were analyzed for each day and week. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Participants With Rescue Medication Usage | Pre-treatment, upto 8 Weeks | The ITT population - all randomized participants who were treated. This population was analyzed based upon the treatment to which participants were randomized. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Adverse Events (AEs) | From the time of informed consent (Screening) until the last study visit (follow-up phone call, Week 10) | Safety population - participants who received at least one dose of study drug. This population was analyzed based upon the actual treatment received. Participants with dosing errors were assigned to a treatment group based upon the treatment they received most often. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02196324/outcomes